Works by Farrington, Daphne

Results: 8

Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer.

Published in:

2017

By:

Infante, Jeffrey;
Patnaik, Amita;
Verschraegen, Claire;
Olszanski, Anthony;
Shaheen, Montaser;
Burris, Howard;
Tolcher, Anthony;
Papadopoulos, Kyriakos;
Beeram, Muralidhar;
Hynes, Scott;
Leohr, Jennifer;
Lin, Aimee;
Li, Lily;
McGlothlin, Anna;
Farrington, Daphne;
Westin, Eric;
Cohen, Roger;
Infante, Jeffrey R;
Verschraegen, Claire F;
Olszanski, Anthony J

Publication type:

journal article

TGF-β signalling-related markers in cancer patients with bone metastasis.

Published in:

Biomarkers, 2008, v. 13, n. 2, p. 217, doi. 10.1080/13547500701676019

By:

Baselga, Jose;
Rothenberg, Mace L.;
Tabernero, Josep;
Seoane, Joan;
Daly, Thomas;
Cleverly, Ann;
Berry, Brandi;
Rhoades, Susanne K.;
Ray, Chad A.;
Fill, Jeffrey;
Farrington, Daphne L.;
Anne Wallace, Lisa;
Yingling, Jonathan M.;
Lahn, Michael;
Arteaga, Carlos;
Carducci, Michael

Publication type:

Article

Homozygous deletions within the 11q13 cervical cancer tumor-suppressor locus in radiation-induced, neoplastically transformed human hybrid cells.

Published in:

Genes, Chromosomes & Cancer, 2004, v. 39, n. 4, p. 277, doi. 10.1002/gcc.20007

By:

Marc S. Mendonca;
Daphne L. Farrington;
Brendan M. Mayhugh;
Yan Qin;
Toni Temples;
Kathleen Comerford;
Rita Chakrabarti;
Kayvan Zainabadi;
J. Leslie Redpath;
Eric J. Stanbridge;
Eri S. Srivatsan

Publication type:

Article

Loss of chromosome 14 increases the radiosensitivity of CGL1 human hybrid cells but lowers their susceptibility to radiation-induced neoplastic transformation.

Published in:

Mutagenesis, 2000, v. 15, n. 3, p. 187, doi. 10.1093/mutage/15.3.187

By:

Mendonca, Marc S.;
Desmond, Lael A.;
Temples, Toni M.;
Farrington, Daphne L.;
Mayhugh, Brendan M.

Publication type:

Article

A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody–drug conjugate, in patients with advanced or metastatic cancer.

Published in:

Investigational New Drugs, 2021, v. 39, n. 6, p. 1613, doi. 10.1007/s10637-021-01146-x

By:

Kollmannsberger, Christian;
Britten, Carolyn D.;
Olszanski, Anthony J.;
Walker, Joan Andrews;
Zang, Wei;
Willard, Melinda D.;
Radtke, David B.;
Farrington, Daphne L.;
Bell-McGuinn, Katherine M.;
Patnaik, Amita

Publication type:

Article

A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer.

Published in:

Investigational New Drugs, 2020, v. 38, n. 4, p. 1145, doi. 10.1007/s10637-019-00873-6

By:

Bendell, Johanna C.;
Bischoff, Helge G.;
Hwang, Jimmy;
Reinhardt, Hans Christian;
Zander, Thomas;
Wang, Xuejing;
Hynes, Scott;
Pitou, Celine;
Campbell, Robert;
Iversen, Philip;
Farrington, Daphne L.;
Bell-McGuinn, Katherine;
Thomas, Michael

Publication type:

Article

Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer.

Published in:

Investigational New Drugs, 2018, v. 36, n. 4, p. 629, doi. 10.1007/s10637-017-0532-2

By:

Goldman, Jonathan W.;
Rosen, Lee S.;
Tolcher, Anthony W.;
Papadopoulos, Kyriakos;
Beeram, Muralidhar;
Shi, Peipei;
Pitou, Celine;
Bell, Robert;
Kulanthaivel, Palaniappan;
Zhang, Xuekui;
Fink, Aaron;
Chan, Edward M.;
Shahir, Ashwin;
Farrington, Daphne;
Patnaik, Amita

Publication type:

Article

A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin.

Published in:

Investigational New Drugs, 2015, v. 33, n. 6, p. 1187, doi. 10.1007/s10637-015-0278-7

By:

Gray, Jhanelle;
Infante, Jeffrey;
Brail, Les;
Simon, George;
Cooksey, Jennifer;
Jones, Suzanne;
Farrington, Daphne;
Yeo, Adeline;
Jackson, Kimberley;
Chow, Kay;
Zamek-Gliszczynski, Maciej;
Burris, Howard

Publication type:

Article